Olarigen
Generic Name
Olaparib
Manufacturer
Example Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olarigen 150 mg tablet | ৳ 833.33 | ৳ 100,000.00 |
Description
Overview of the medicine
Olarigen (Olaparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor used for the treatment of certain types of cancer, including ovarian, breast, prostate, and pancreatic cancer, particularly in patients with BRCA gene mutations.
Uses & Indications
Dosage
Adults
300 mg (two 150 mg tablets) orally twice daily. Continue treatment until disease progression or unacceptable toxicity.
Elderly
No specific dosage adjustment required, but monitor for adverse reactions.
Renal_impairment
For moderate renal impairment (creatinine clearance 31-50 mL/min), reduce dosage to 200 mg (two 100 mg tablets) twice daily. Not studied in severe renal impairment (CrCl <30 mL/min).
How to Take
Administer orally, with or without food. Tablets should be swallowed whole and not chewed, crushed, or dissolved.
Mechanism of Action
Olaparib inhibits PARP enzymes, which are involved in DNA damage repair. By inhibiting PARP, Olaparib traps PARP on DNA breaks, leading to accumulation of DNA damage and cell death, particularly in cancer cells with homologous recombination deficiency (e.g., BRCA mutations).
Pharmacokinetics
Onset
Not directly quantifiable for clinical effects; PARP inhibition begins shortly after administration.
Excretion
Eliminated via both renal (approximately 44%) and fecal (approximately 42%) routes.
Half life
Mean terminal half-life is approximately 15-17 hours.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations (Cmax) achieved typically within 1-2 hours.
Metabolism
Extensively metabolized, primarily by cytochrome P450 (CYP) 3A4.
Side Effects
Contraindications
- •Known hypersensitivity to Olaparib or any of its excipients.
- •Pregnancy and breastfeeding (due to potential fetal harm).
Drug Interactions
Moderate CYP3A inhibitors (e.g., erythromycin, diltiazem)
Concomitant use increases Olaparib exposure; reduce Olaparib dose to 150 mg twice daily.
Strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John's wort)
Concomitant use decreases Olaparib exposure; avoid concomitant use.
Strong CYP3A inhibitors (e.g., itraconazole, clarithromycin, grapefruit juice)
Concomitant use increases Olaparib exposure; reduce Olaparib dose to 100 mg twice daily.
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep in original package to protect from moisture. Do not refrigerate or freeze.
Overdose
There is no specific antidote for Olaparib overdose. In the event of an overdose, treatment should be symptomatic and supportive. Monitor for hematologic and other adverse reactions.
Pregnancy & Lactation
Olaparib can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose. It is unknown if Olaparib is excreted in human milk; due to the potential for serious adverse reactions in a breastfed infant, advise women not to breastfeed during treatment and for 1 month after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24-36 months
Availability
Specialized pharmacies, hospitals
Approval Status
FDA approved
Patent Status
Patented
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
